ALX On­col­o­gy won’t seek ap­proval for CD47 drug in gas­tric can­cer; Ko­r­ro Bio’s lay­offs

Plus, news about Cog­ni­tion Ther­a­peu­tics, Sagimet Bio­sciences, BeiGene, Hik­ma and Rally­bio:

ALX On­col­o­gy won’t pur­sue ap­proval in gas­tric can­cer: The com­pa­ny had been aim­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER